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Abstract
Background Identification of patients with necrotizing pancreatitis at high risk for a complicated course could facilitate clinical
decision-making. In multiple diseases, several parameters of body composition are associated with impaired outcome, but studies
in necrotizing pancreatitis are lacking.
Methods A post hoc analysis was performed in a national prospective cohort of 639 patients with necrotizing pancreatitis.
Skeletal muscle mass, skeletal muscle density, and visceral adipose tissue were measured at the third lumbar vertebra level
(L3) on contrast-enhanced computed tomography (CT) within 10 days after initial admission and 1 month thereafter.
Results In total, 496 of 639 patients (78%) were included. Overall mortality rate was 14.5%. Skeletal muscle mass and density
and visceral adipose tissue on first CT were not independently associated with in-hospital mortality. However, low skeletal
muscle density was independently associated with increased mortality in patients ≥65 years (OR 2.54 (95%CI 1.12–5.84,
P = 0.028). Skeletal muscle mass and density significantly decreased within 1 month, for both males and females, with a median
relative loss of muscle mass of 12.9 and 10.2% (both P < 0.001), respectively. Skeletal muscle density decreased with 7.2 and
7.5% (both P < 0.001) for males and females, respectively. A skeletal muscle density decrease of ≥10% in 1 month was
independently associated with in-hospital mortality: OR 5.87 (95%CI 2.09–16.50, P = 0.001).
Conclusion First CT-assessed body composition parameters do not correlate with in-hospital mortality in patients with necro-
tizing pancreatitis. Loss of skeletal muscle density ≥10% within the first month after initial admission, however, is significantly
associated with increased mortality in these patients.
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Introduction
Acute pancreatitis is the most common reason for acute gas-
trointestinal hospital admission.1 Necrotizing pancreatitis de-
velops in around 20% of patients.2
,3 Depending on the pres-
ence of organ failure, necrotizing pancreatitis is classified as
moderate severe or severe pancreatitis.4 Mortality increases,
and severe morbidity rates exceed 40%, particularly when the
necrosis is infected.5 Infected necrosis occurs in around 30%
of patients with necrotizing pancreatitis and is in general an
indication for invasive intervention (i.e., catheter drainage, if
necessary followed by a necrosectomy).6
,7 Necrotizing pan-
creatitis is characterized by a variable clinical course. To fur-
ther improve outcome of patients with necrotizing pancreati-
tis, identification of determinants associated with high risk of
mortality is needed in these patients. Several scoring systems,
both radiological and clinical, have been developed to predict
the severity of acute pancreatitis at hospital admission with
comparable moderate accuracy for predicting mortality.8 All
radiologic scoring systems focus on pancreatitis-associated
findings (such as necrosis, pancreatic collections, and inflam-
matory changes), but factors associated with body composi-
tion are not part of any of these systems.
Body composition parameters that can easily and re-
liably be assessed on computed tomography (CT), such
as skeletal muscle mass and skeletal muscle density
(i.e., a measure for skeletal muscle quality and intra-
muscular fat infiltration), are predictive factors for poor
outcome in various populations, particularly within sur-
gical oncology,9
,10 but also in liver transplant, vascular
surgery, intensive care, and trauma patients.11
–14
Furthermore, the loss of skeletal muscle mass, for ex-
ample during chemotherapy, is associated with poor
outcome.15 Visceral adipose tissue, the metabolically ac-
tive component of total body adipose tissue, is another
body composition measure that can be assessed on CT.
Visceral obesity is associated with impaired outcome
after surgery for various malignancies, such as colorec-
tal, adrenorenal, and hepatocellular carcinoma.16
–18
Moreover, a recent study suggests that android fat dis-
tribution may predict the severity of acute pancreatitis.19
Therefore, the aim of this study was to investigate the as-
sociation between parameters of body composition (i.e., skel-
etal muscle mass, skeletal muscle density, and visceral adipose
tissue) at onset of disease with in-hospital mortality in patients
with necrotizing pancreatitis and to analyze whether skeletal
muscle loss during the course of disease is associated with
mortality in these patients.
Methods
Patients
A post hoc analysis of a prospective, observational cohort
consisting of 639 necrotizing pancreatitis patients was per-
formed. This cohort was collected in 21 Dutch hospitals (eight
Dutch university medical canters and 13 teaching hospitals)
from 2004 to 2008.3 All patients who had an abdominal CT
examination performed of sufficient quality (i.e., complete
images, no artifacts, and contrast-enhanced) within the first
10 days after initial admission were included. Patients with
unknown body height were excluded from analyses including
skeletal muscle mass, because skeletal muscle mass is
expressed in the L3 muscle index (cm2/m2).23 Furthermore,
CTs performed 30 days (±15 days) thereafter were also col-
lected (i.e., 1-month CT). Skeletal muscle depletion was de-
fined as a decrease exceeding 10% percent, as this was con-
sidered clinically relevant. Severe skeletal muscle depletion
was defined as a decrease exceeding 25%.
Skeletal Muscle and Adipose Tissue Measurements
Body composition measurements were performed on routine-
ly performed contrast-enhanced abdominal CTs using FatSeg.
This software program was developed at the Erasmus MC
University Medical Center to perform cross-sectional soft tis-
sue (i.e., skeletal muscle and adipose tissue) measurements on
CT using the MeVisLab development environment for medi-
cal image processing and visualization version 2.4 (available
from http://www.mevislab.de), as previously described.20 In
short, the cross-sectional skeletal muscle mass area was mea-
sured with manually tracing inner and outer contours using a
preset Hounsfield unit (HU) range of −30 to +150 on the level
of the third lumbar vertebra (L3) on which both transversal
processes were visible. The following muscles were included:
psoas, paraspinal, transverse abdominal, external oblique, in-
ternal oblique, and rectus abdominis. The cross-sectional skel-
etal muscle area was corrected for height squared (m2),
resulting in the L3 muscle index (cm2/m2).21 Mean skeletal
muscle attenuation (in HU) was used as a measure of skeletal
muscle density, with low skeletal muscle density reflecting
high intramuscular adipose tissue infiltration and poor skeletal
muscle quality.22
,23 Visceral adipose tissue measurements
were performed on the same slice with a preset HU
range of −190 to −30. Selected intraluminal bowel con-
tent expressing the same radio density as adipose tissue
was manually erased. Sex-specific tertiles for the body
composition parameters were created. Data of our re-
search group showed high inter- and intra-observer
agreement for skeletal muscle and adipose tissue mea-
surements on CT.24
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Baseline Characteristics
Baseline characteristics collected at admission at onset of dis-
ease were age, sex, body mass index (BMI, kg/m2), disease
etiology, American Society of Anesthesiologists (ASA) clas-
sification, and the presence of organ failure at admission.
Furthermore, the following clinical scores to predict the sever-
ity of pancreatitis were calculated: Acute Physiologic and
Chronic Health Evaluation (APACHE) II score and
Modified Glasgow score (i.e., Imrie score), with parameters
collected within 24 and 48 h after admission, respectively.
Additionally, the highest C-reactive protein (CRP) level in
the first 48 h of admission was collected. APACHE II score
(≥8), Modified Glasgow score (≥3), and CRP levels
(≥150 mg/L) are previously described predictors for disease
severity in acute pancreatitis.25
–28 Necrotizing pancreatitis was
defined according to the 2012 revised Atlanta classification.4
The presence of necrotizing pancreatitis was assessed on all
baseline CTs by an experienced abdominal radiologist (TLB).
Study Outcomes
The primary outcome was mortality during initial admission.
Furthermore, the changes in skeletal muscle mass and skeletal
muscle density between the baseline CTand CTafter 1 month
were calculated. Since there is great inter-slice variability in
visceral adipose tissue due to the position of visceral organs
and the potential development of (peri)pancreatic necrosis
over time, this measurement was only performed on baseline
CTs at onset of disease.
Statistical Analysis
Data were analyzed using IBM SPSS Statistics for Windows,
version 22.0 (IBM Corp., Armonk, NY, USA). Outcomes
were reported as absolute numbers and percentages for cate-
gorical variables. Continuous variables were summarized as
either means with corresponding standard deviations (SD) or
interquartile ranges (IQR) depending on normality of distribu-
tion. The chi-square test was used to compare categorical var-
iables. T tests were used for normally distributed continuous
variables and the Mann–WhitneyU test for non-normally dis-
tributed continuous variables. The change in skeletal muscle
mass was assessed using the non-parametric paired Wilcoxon
test. Univariable logistic regression analysis was performed to
identify parameters that were associated with the outcome
measures. Parameters that were associated in univariable anal-
ysis (P < 0.100) were entered into a multivariable logistics
regressions analysis (backward stepwise elimination method).
A two-sided P value below 0.05 was considered statistically
significant for all statistical tests. First, the association be-
tween the body composition measures and in-hospital mortal-
ity was evaluated, followed by the association between the
loss in skeletal muscle mass and density and mortality.
Parameters representing disease severity (e.g., APACHE II
and Modified Glasgow score) were excluded from this analy-
sis, because these were assessed within the first 48 h of ad-
mission. Receiver Operation Characteristic (ROC) curves
with corresponding areas under the curve (AUC) were created
to test the predictive accuracy of known predictive scores (i.e.,
APACHE II score, Modified Glasgow score, and highest CRP
level in the first 48 h of admission) and the CT-assessed body
composition parameters. An AUC of 0.91–1.00 was consid-
ered excellent, 0.81–0.90 good, 0.71–0.80 fair, 0.61–0.70
poor, and 0.51–0.60 very poor.
Results
Patients and Baseline Characteristics
Of 639 patients, 143 patients (22%) were excluded either
because the baseline CT was performed later than 10 days
after initial admission, no sufficient (assessable) CTwas avail-
able, or no contrast-enhanced CTwas performed (Fig. 1). The
final study cohort consisted of 496 patients (62% males) with
a median age of 58 (IQR 45–70) and BMI of 26.7 (IQR 25.0–
30.2) kg/m2. Baseline characteristics of the included patients
are shown in Table 1. Baseline characteristics and study out-
come (in-hospital mortality) did not significantly differ be-
tween included and excluded patients, except the presence of
pancreatic necrosis (included patients 48.4% versus excluded
patients 58.7%, P = 0.029) and BMI (included patients medi-
an BMI 26.7 kg/m2 versus excluded patients median BMI
28.9 kg/m2, P = 0.044). Body height was unknown for 94
(19.0%) patients.
Body Composition Measurements
For males, the median L3 muscle index and muscle density
were 53.7 (IQR 47.5–59.4) cm2/m2 and 34 (28–40) HU, re-
spectively, and for females 44.6 (IQR 38.6–50.2) cm2/m2 and
28 (IQR 20–35) HU, respectively. The median visceral adi-
pose tissue area was 234.3 (IQR 172.2–308.1) cm2 for males
and 156.8 (IQR 104.1–220.0) cm2 for females.
Association of Body Composition with Mortality
The median time interval between initial admission and the
first abdominal CT was 2 days (IQR 0–5). The mortality rate
was 14.5% (72/496) and did not significantly differ between
included and excluded (14.7%) patients (P = 0.960). A non-
significant association between the lowest L3 muscle index
tertile and mortality was found (OR 0.976 (95%CI 0.507–
1.878), P = 0.942). Significant univariable associations bet-
ween the lowest HU tertile and highest VAT tertile and
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mortality were found. Nevertheless, the lowest HU tertile and
the highest VAT tertile were not independently associated with
mortality in multivariable analysis after correcting for age,
ASA classification, the presence of pancreatic necrosis, and
the presence of organ failure at admission: adjusted OR 1.132
(95%CI 0.617–2.078), P = 0.688 and 1.311 (95%CI 0.732–
2.349), P = 0.363 (Table 2).
As skeletal muscle mass and density are strongly associat-
ed with age,29 subgroup analyses were performed in patients
aged <65 and ≥65 years. Patients aged ≥65 in the lowest
skeletal muscle density tertile showed an increase mortality
rate (29.3%) compared with patients in the mid and highest
tertile (13.5%), P = 0.008. Skeletal muscle density in the low-
est tertile was associated with an increased risk of in-hospital
mortality (adjusted OR 2.54 (95%CI 1.12–5.84),P = 0.025) in
patients ≥65 years, independently of ASA classification, or-
gan failure at admission, and pancreatic necrosis. An incre-
mental increase in skeletal muscle density showed a protective
effect on mortality (adjusted OR 0.94 (95%CI 0.90–0.99),
P = 0.010).
Predictive Accuracy of Established Risk Parameters
and Body Composition Parameter
The ROC curves are depicted in Fig. 2, for males and females,
separately. In males (Fig. 2a), APACHE II and Modified
Glasgow scores showed a poor predictive value (AUC 0.62
and 0.62, respectively) and all body composition parameters a
very poor predictive value (AUC ranging from 0.53 to 0.59).
In females (Fig. 2b), APACHE II andModifiedGlasgow score
showed a fair predictive value with AUCs of 0.72 and 0.80,
respectively. Skeletal muscle and visceral adipose tissue mass
showed a very poor predictive value (AUC 0.52 and 0.59,
respectively), whereas skeletal muscle density showed a fair
predictive value with an AUC of 0.71.
SkeletalMuscleMass and Density Loss During the Disease
Course
In total, 189 patients (66.7%male, median age 58 years) had a
baseline CT and a CT 1 month thereafter with a median time
interval of 29 (IQR 25–33) days. In-hospital mortality in these
patients was 14.3% (27/189). For males, the median skeletal
muscle mass (i.e., cross-sectional skeletal muscle area) de-
creased from 169.7 (IQR 153.2–193.9) cm2 to 147.9 (IQR
131.5–166.7) cm2 and for females from 125.2 (IQR 112.1–
137.3) cm2 to 111.9 (98.9–121.6) cm2 (both P < 0.001). This
639 patients in the original cohort
-32 (5%) patients with CT > 10 
days after initial admission
-89 (14%) patients with
no or a non-assessable CT 
496 (78%) patients included in 
current study
-22 (3%) patients
without contrast-enhanced CT
Fig. 1 Inclusion flowchart
Table 1 Baseline characteristics of 496 patients with necrotizing
pancreatitis
Characteristic All patients (n = 496)
Age, years (IQR) 58 (45–70)
Males (%) 308 (62)
BMI, kg/m2 (IQR)a 26.7 (25.0–30.2)
<18.5 (%) 3 (1)
18.5–24.9 (%) 61 (25)
25–29.9 (%) 120 (48)
≥30 (%) 64 (26)
Etiology (%)
Biliary 240 (48)
Alcohol 114 (23)
Other 51 (10)
Unknown 91 (18)
ASA classification on admission (%)
I (healthy status) 149 (30)
II (mild systemic disease) 272 (55)
III (severe systemic disease) 75 (15)
Organ failure at admission (%) 52 (11)
Predicted severity of pancreatitis
APACHE II score on admission (IQR) 8 (5–11)
APACHE II score ≥8 on admission (%) 254 (51)
Modified Glasgow score within
first 48 h of admission (IQR)
3 (2–5)
Modified Glasgow score ≥3 (%) 320 (65)
Highest CRP level in first 48 h
of admission, mg/L (IQR)
291 (213–381)
CRP level ≥150 mg/L (%)b 397 (86)
Pancreatic necrosis (%) 240 (48)
Time between admission and 1-month
CT, days (IQR)
2 (0–5)
Continuous variables are provided as mean (±Standard Deviation [SD])
or median (interquartile range [IQR]) depending on normality of
distribution
BMI body mass index, ASA American Society of Anesthesiologists,
APACHE-II Acute Physiologic and Chronic Health Evaluation
(APACHE)-II, CRP C-reactive protein, CT computed tomography
aAvailable for 248 patients
b Available for 463 patients
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resulted in a median relative difference of 12.9% (IQR 5.8–
20.9) and 10.2% (IQR 1.4–18.8), respectively. For males, the
median skeletal muscle density decreased from 33 (IQR 27–
39) HU to 31 (IQR 23–38) HU and for females from 27 (IQR
20–33) HU to 23 (IQR 15–35) HU (both P < 0.001), with
median relative differences of 7.2% (IQR −9.1–22.7) for
males and 7.5% (IQR −15.0–32.3) for females. Corrected
for the time interval between the baseline CT and the follow-
up CT, significant decreases in cross-sectional skeletal muscle
area of 0.43% (IQR 0.15–0.72) and in skeletal muscle density
of 0.28% (IQR −0.41–0.97) per day were observed (P < 0.001
and P = 0.035, respectively).
In total, 110 (58.2%) patients lost ≥10% of cross-sectional
skeletal muscle area. Eighty-nine (47.1%) patients experi-
enced ≥10% decrease in skeletal muscle density. Mortality
rate was not significantly different between patients with com-
pared to patients without ≥10% skeletal muscle mass loss
(14.5 versus 13.9%, P = 0.904), whereas patients with ≥10%
decrease in skeletal muscle density showed an increased risk
of mortality (24.7 versus 5.0%, P < 0.001). More than 10%
skeletal muscle density loss (adjusted OR 5.87 (95%CI
2.09–16.50), P = 0.001) was an independent risk factor for
in-hospital mortality, after correcting for sex and age
(Table 3). These patients had a significantly longer hospital
(median 70 (IQR 45–106) versus 45 (IQR 23–71) days,
P < 0.001) and intensive care unit (median 0 (IQR 0–11) ver-
sus 14 (IQR 2–38) days, P < 0.001) stay compared with pa-
tients <10% skeletal muscle density loss. Twenty-eight
(14.8%) and 48 (25.4%) patients experienced decreases in
skeletal muscle mass and density that exceeded 25%. More
than 25% skeletal muscle mass loss was not independently
associated with increased in-hospital mortality (adjusted OR
2.72 (95%CI 0.98–7.56), P = 0.055) after correcting for age,
while a decrease of ≥25% skeletal muscle density was associ-
ated with increased in-hospital mortality (adjusted OR 5.4
(95%CI 2.25–13.04), P < 0.001).
Discussion
This is the first, multicenter study to analyze the association
between CT-assessed body composition parameters and mor-
tality in patients with necrotizing pancreatitis. None of the
early body composition parameters chosen was associated
with in-hospital mortality overall. Nevertheless, low skeletal
muscle density was independently associatedwithmortality in
patients aged ≥65. Furthermore, our data suggest that skeletal
muscle depletion of ≥10% after 1 month in patients with nec-
rotizing pancreatitis may identify patients at risk for mortality.
Table 2 Univariable and
multivariable logistic regression
analysis for risk factors for in-
hospital mortality (n = 496, 72
patients deceased)
Univariable
OR (95% CI)
P Multivariable
OR (95% CI)
P
Sex (male) 0.78 (0.47–1.29) 0.331
Age (years) 1.04 (1.02–1.06) <0.001 1.04 (1.02–1.06) <0.001
BMI (kg/m2)a
20.0–24.9 (normal) 1 (ref)
<18.5 vs normal 2.55 (0.21–30.89)
>25.0–29.9 vs normal 0.62 (0.26–1.51)
≥30 vs normal 0.73 (0.27–1.99) 0.553
ASA I–II 1 (ref)
ASA III 4.33 (2.46–7.62) <0.001 4.026 (2.17–7.49) <0.001
Organ failure at admission 5.22 (2.79–9.76) <0.001 5.49 (2.74–10.99) <0.001
Pancreatic necrosis 2.42 (1.43–4.09) 0.001 2.98 (1.65–5.38) <0.001
L3 muscle index (cm2/m2)
Highest and mid tertile 1 (ref)
Lowest tertile 0.98 (0.51–1.88) 0.942
Skeletal muscle density (HU)
Highest and mid tertile 1 (ref)
Lowest tertile 2.37 (1.43–3.92) 0.001 1.13 (0.62–2.08) 0.688
VAT (cm2)
Highest and mid tertile 1 (ref)
Lowest tertile 1.88 (1.130–3.13) 0.015 1.31 (0.73–2.35) 0.363
BMI body mass index, ASA American Society of Anesthesiologists, VAT visceral adipose tissue area, OR odds
ratio, CI confidence interval
a Available for 248 patients
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We hypothesized that CT-assessed skeletal muscle mass
corrected for body height (lowL3muscle index)was associated
with impaired outcome in patients with necrotizing pancreatitis.
Although the association between body composition (i.e., skel-
etal muscle and visceral adipose tissue mass) and outcome has
been investigated extensively in cancer populations,9
,10 some
studies have shown its association in benign diseases.11
–14 Low
skeletal muscle density was shown to be of prognostic value in
patients with renal cell carcinoma,30 lymphoma,31 melanoma,32
and various other malignancies.22 Moreover, a previous study
reported lower mean values of the cross-sectional muscle area,
as well as a lower mean BMI in patients with chronic pancre-
atitis compared with the current study cohort.33 In the current
study among patients with necrotizing pancreatitis, however,
neither skeletal muscle mass nor density was related to
mortality in the overall population. There are two possible ex-
planations for the differing findings. First, the acute onset of the
disease in these a priori relatively healthy patients (85% ASA
classification 1–2) could explain the higher index values in our
cohort as there was no underlying disease or catabolic state
before. Previous studies on this topic primarily investigated
patients with metabolically active diseases (e.g., cancer pa-
tients) or those with chronic illnesses (e.g., patients awaiting
liver transplantation for cirrhosis, patients with chronic
pancreatitis). Second, higher age is a significant determinant
for sarcopenia (i.e., the involuntary loss of skeletal muscle mass
and strength). Prior studies predominantly included older pa-
tients (e.g., patients with cancer or abdominal aortic aneurysm),
whereas the age of patients with necrotizing pancreatitis is
usually considerably lower (median age of 58 years in our
Fig. 2 Receiver Operating
Curves (ROC) for severity scores
(i.e., APACHE II and Modified
Glasgow scores) and CT-assessed
body composition parameters.
Skeletal muscle density (HU) and
mass (cm2/m2) values have been
inverted because lower values
represent higher risk. aMales. b
Females
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study). Our finding in older patients is in line with a previous
study on short-term outcomes in colorectal cancer patients.
Especially in patients ≥65 years of age, an association was
found with increased infectious complication rates, inpatient
rehabilitation care, and consequently prolonged hospital stay.29
Besides skeletal muscle mass and density, the amount of
visceral adipose tissue was also not associated with mortality
in patients with necrotizing pancreatitis in the current study.
This is in line with a previous study, which found no relation-
ship between adipose tissue distribution and pancreatitis
severity.34 In this particular study, obese patients showed
worse predicted severity scores (e.g., by the Ranson score),
but abdominal fat distribution was not independently associ-
ated with the actual acute pancreatitis severity and mortality.
Another recent study found no difference in clinical outcome
in ICU-admitted acute pancreatitis patients with or without a
decrease in visceral adipose tissue mass.35 Future studies
should further address whether routine assessment of these
body composition parameters could be of added value in cur-
rent (CT) severity index models.
Although necrotizing pancreatitis is innately a benign dis-
ease, it is characterized by a striking hypercatabolic metabolic
state. Based on results of this study, this leads to considerable
skeletal muscle loss within 1 month in some patients, which is
comparable with or even larger than the loss in palliative can-
cer patients in 3 to 6 months.36 Previous studies showed that
both prolonged hospital stay and inflammatory processes
(such as acute pancreatitis) are known to be associated with
skeletal muscle depletion.37
,38 Also, a significant decrease in
skeletal muscle mass has previously been described in various
cancer patients undergoing (neo)adjuvant chemotherapy or
chemo-radiation therapy. This was associated with increased
incidence of postoperative complications in esophageal cancer
patients.37 Furthermore, a decreased survival has been report-
ed in colorectal cancer patients who experienced skeletal
muscle depletion,39
,40 but not in esophagogastric cancer
patients.41
,42 Interestingly, in patients with necrotizing
pancreatitis, we found that substantial loss of skeletal muscle
density (7.2 and 7.5% for males and females, respectively) in
the first month after initial admission significantly correlated
with mortality. The differing and positive effect of the decline
of skeletal muscle mass on mortality in necrotizing
pancreatitis compared with other diseases likely relates to
the intensity and degree of its loss within a shorter period of
time. As such, considerable loss of skeletal muscle mass and
density during the course of acute pancreatitis correlates with
disease severity and can identify those at high risk of mortal-
ity. Furthermore, it is conceivable that considerable alterations
in body composition may prolong the period of convalescence
in those who survive. A previous study among acute pancre-
atitis patients who were admitted at the ICU found no skeletal
muscle mass loss, whereas a significant decrease in visceral
adipose tissue mass was observed.35 However, this study co-
hort consisted of only 21 patients and the time interval be-
tween CTs was not described. Furthermore, inter-slice vari-
ability in visceral adipose tissue due to the position of visceral
organs and the potential development of (peri)pancreatic ne-
crosis over time may have contributed to the significant de-
tected decrease in visceral adipose tissue mass, whereas skel-
etal muscle mass has been measured more reliably.
Our findings support the potential beneficial effects of nu-
tritional support in acute pancreatitis. In the early phase, nu-
trition is essential as it maintains gut function, prevents ileus,
and reduces bacterial overgrowth.43 Both in the early and late
phases of the disease, active nutrient repletion helps tissue
repair and healing and may potentially minimize alterations
in body composition. However, nutritional support only, as
any other monotherapy, will probably not be sufficient.44
Therefore, future research should focus on nutritional support
and other pharmacological agents to counterbalance the detri-
mental effects of skeletal muscle depletion in patients with
necrotizing pancreatitis.44 Alternative treatment options, such
as myostatin inhibition, which reduces skeletal muscle
wasting,45 are currently being investigated in phase II clinical
trials in cancer patients46 and might prove useful in acute
pancreatitis. Future studies on this topic are highly warranted.
This study has some limitations. First, patients were divid-
ed in sex-specific tertiles rather than using dichotomous cut-
off values, since commonly used cut-off values to classify
patients as (non)sarcopenic have been derived only in cancer
patients.20
–22 Using optimal stratification to find cut-off
values, as has been performed in previous studies,20
,21 was
not possible due to the dichotomous character of our primary
study end-point (i.e., in-hospital mortality). Another limitation
Table 3 Association between
skeletal muscle mass and skeletal
muscle density loss within
1 month and mortality (n = 189,
27 patients deceased)
Univariable
OR (95% CI)
P Multivariable
OR (95% CI)
P
Sex (male) 0.688 (0.30–1.59) 0.380 0.82 (0.33–2.04) 0.669
Age (years) 1.045 (1.01–1.08) 0.007 1.04 (1.01–1.08) 0.016
≥10% Skeletal muscle mass loss (cm2) 1.05 (0.46–2.41) 0.904 0.75 (0.29–1.93) 0.556
≥10% Skeletal muscle density loss (HU) 6.24 (2.25–17.30) <0.001 5.87 (2.09–16.50) 0.001
OR odds ratio, CI confidence interval
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is that our results apply only to patients who eventually deve-
lop necrotizing pancreatitis. We feel, however, that inclusion
of patients with interstitial disease would not have altered our
results in a meaningful way, as mortality is rare in patients
with interstitial pancreatitis, who in general recover fast and
uneventfully. Finally, as described previously, CTs were not
performed routinely or at regular time intervals, but only in
patients who showed predicted severe pancreatitis, deteriorated
or did not improve clinically.3 This explains the short median
time interval of 2 days between admission and the first CT.
Furthermore, the comparable mortality rates between the entire
cohort (14.5%) and the cohort of patients who had a CT after
1 month (14.3%) suggest that patients who had no CT after
1 month either had deceased or experienced an uneventful
recovery and that early body composition was not associated
with mortality. Consequently, this may have led to selection
bias and results should therefore be interpreted with caution.
In conclusion, neither early skeletal muscle mass and den-
sity nor visceral adipose tissue mass are associated with in-
hospital mortality in patients with necrotizing pancreatitis.
However, low skeletal muscle density was independently as-
sociated with in-hospital mortality in patients ≥65 years.
Furthermore, significant decreases in skeletal muscle mass
and density were observed in the first month after initial ad-
mission. A decrease of ≥10% in skeletal muscle density within
the first month after admission may identify patients at in-
creased risk for mortality. Future prospective studies should
investigate the true value of CT-assessed skeletal muscle mass
and density, visceral adipose tissue, and its losses, to predict
patient outcome in acute (necrotizing) pancreatitis and deter-
mine whether (prophylactic) treatment allows counteracting
the deleterious effects of body composition alterations.
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